Shares of The Cooper Companies cratered to $53.66 Wednesday morning after the medical device maker's fiscal third-quarter report exposed stalling growth in its core contact lens business and forced management to slash its full-year outlook. The question for investors: is this pain temporary or structural?
Revenue Missed by $40 Million, and Almost All of It Came from Contact Lenses
Revenue increased about 1% organically to $1.07 billion, but missed forecasts by roughly $30 million.
The revenue miss was concentrated in CooperVision, where sales were flat year over year at $717 million.
Sales in the Americas declined 2%, and management said a proactive reduction in U.S. channel inventory hurt Q3 and will continue to affect Q4.
Americas organic growth would have been about 5% higher in Q3 without this action. That's a massive gap between sell-through (what consumers actually buy) and sell-in (what distributors order), which makes it hard for investors to gauge true demand.
The Guidance Cut Landed Well Below Where Wall Street Was Sitting
Full-year revenue guidance was reduced to $4.229–$4.252 billion from the $4.285–$4.321 billion range issued in June — a midpoint drop of about $62.5 million.
Fourth-quarter adjusted earnings are now expected at $1.05–$1.09, well below the roughly $1.20 consensus before the report.
Full-year adjusted EPS guidance of $4.51–$4.55 also came in below the $4.63 consensus. When both the top and bottom lines disappoint simultaneously, the selloff tends to be severe — and it was.
The Strategic Review Ended With No Sale, Removing a Catalyst
The board concluded that shareholders are better served by continued ownership rather than pursuing a transaction at this time. Investors who had hoped a potential sale of the surgical unit would unlock value got nothing. Instead, they got a $1 billion expansion of the share buyback program — but Cooper spent $339 million buying 4.9 million shares last quarter at an average of $69.16, roughly 30% above the current after-hours price. That's a painful look for capital allocation.
Record Cash Flow Is Real, but It Needs to Outlast the Inventory Hangover
Free cash flow rose 66% to a record $273 million. That's genuinely strong. But the near-term test is whether CooperVision's inventory correction ends in Q4 or spills into fiscal 2027. CEO Al White insists demand is healthy: "We're now positioned to enter fiscal 2027 with a healthier channel and stronger foundation." The market clearly isn't buying it yet.